| abstract |
The present invention relates to antigen-recognizing constructs against COL6A3 antigens. In particular, the invention provides novel T cell receptor (TCR) based molecules that are selective and specific for the tumor expressed antigen COL6A3. The TCR and COL6A3 antigen-binding fragments derived therefrom are useful in the diagnosis, treatment and prevention of COL6A3-expressing cancers. Furthermore, nucleic acids encoding the antigen-recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen-recognizing constructs, and pharmaceutical compositions comprising the compounds of the invention are provided. |